In 2020, pemigatinib was approved by the FDA as the first targeted therapy in advanced cholangiocarcinoma and in August 2022 as a treatment for relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement [17, 18]. The gene discussed is FGFR1; the disease is cholangiocarcinoma.